Regeneron 20145 - mAb treatment in outpateints with COVID-19 - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the study drug and understand if it can help decrease the amount of medical visits people with COVID-19 have to complete.

What is the Condition Being Studied?

COVID-19

Who Can Participate in the Study?

Adults who:
-Have been diagnosed with COVID-19 within the last 3 days
-Have not been admitted to the hospital

Age Group
Adults

What is Involved?

If you agree to be in this study you will:
- Be randomly assigned to receive one dose of the study drug or a placebo (harmless saline) either through a vein in your arm or an injection under your skin
- Have nasopharyngeal (upper throat behind your nose) swabs and blood taken several times in the first 3 weeks of the study
- Have blood taken again at 4 months
- Have up to several phone calls with the study team over the next 5 months.

Study Details

Full Title
A PHASE 2 STUDY TO ASSESS THE VIROLOGIC EFFICACY OF REGN10933+REGN10987 ACROSS DIFFERENT DOSE REGIMENS IN OUTPATIENTS WITH SARS-CoV-2 INFECTION
Principal Investigator
Emergency Medicine Specialist
Protocol Number
IRB: PRO00107409
NCT: NCT04666441
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698